(NASDAQ: VERU) Veru's forecast annual revenue growth rate of 16.49% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 81.85%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.63%.
Veru's revenue in 2025 is $6,656,522.On average, 1 Wall Street analysts forecast VERU's revenue for 2025 to be $51,276,372, with the lowest VERU revenue forecast at $51,276,372, and the highest VERU revenue forecast at $51,276,372. On average, 1 Wall Street analysts forecast VERU's revenue for 2028 to be $732,519,600, with the lowest VERU revenue forecast at $732,519,600, and the highest VERU revenue forecast at $732,519,600.
In 2029, VERU is forecast to generate $1,831,299,000 in revenue, with the lowest revenue forecast at $1,831,299,000 and the highest revenue forecast at $1,831,299,000.